Haemophagocytic lymphohistiocytosis in an adult with postacute COVID-19 syndrome

Daniel Wiseman,1 John Lin,2 Jean-Pierre Routy,3,4 Gordan Samoukovic5

1Division of Internal Medicine, McGill University Health Centre, Montreal, Québec, Canada
2Infectious Diseases and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montréal, Québec, Canada
3Research Institute of the McGill University Health Centre, Montreal, Québec, Canada
4Division of Haematology, McGill University Health Centre, Montreal, Québec, Canada
5Division of Critical Care Medicine, McGill University Health Centre, Montreal, Québec, Canada

SUMMARY
Haemophagocytic lymphohistiocytosis (HLH) causing multiorgan failure has been reported as an acute clinical presentation of COVID-19. However, the literature surrounding HLH in the context of a postacute COVID-19 syndrome is limited. This report presents a case of a life-threatening HLH occurring 6 weeks after a pauci-symptomatic COVID-19 infection in a previously healthy adult. A bone marrow aspirate confirmed the HLH and the patient was successfully treated with dexamethasone and etoposide. To our knowledge, this is the first case of HLH occurring as a postacute COVID-19 syndrome following a pauci-symptomatic initial infection.

BACKGROUND
According to the WHO, there are currently over 164 million confirmed cases of COVID-19 worldwide, including over 3 million deaths.1 Macrophage activation, and more specifically haemophagocytic lymphohistiocytosis (HLH), is one among many acute clinical presentations of COVID-19, and is a medical emergency with a poor prognosis.2

Recently, Nalbandian et al3 defined postacute COVID-19 syndrome as persistent symptoms and/or delayed or long-term complications of SARS-CoV-2 infection beyond 4 weeks from the onset of symptoms. As it stands, the severity of the initial COVID-19 illness is considered a risk factor for developing postacute COVID-19 syndrome. Despite the elaborate list of possible manifestations of the postacute COVID-19 syndrome, HLH is not mentioned.3 This report presents the first case of a life-threatening HLH occurring 6 weeks after a pauci-symptomatic COVID-19 infection, and therefore suggests that HLH can manifest as a postacute COVID-19 syndrome.

CASE PRESENTATION
A 54-year-old multiracial man originally from the Dominican Republic presented with a 2-day history of fever, acute right-sided anterior neck pain and neck swelling. His medical history was limited to a prior episode of uncomplicated sigmoid diverticulitis.

Six weeks prior to the current emergency room (ER) visit, the patient was diagnosed with COVID-19, confirmed by PCR via nasopharyngeal swab. At the time, he experienced fever and chest tightness. As the patient did not feel overly encumbered by his illness, he simply self-isolated and his symptoms resolved within 1 week without treatment. No physical examination or laboratory testing was performed. According to the patient, he was not re-exposed to COVID-19 prior to his current ER visit; he was, however, in public areas.

At the current presentation, a CT scan of the neck revealed multiple, enlarged, right cervical lymph nodes with surrounding fat stranding. A presumed diagnosis of cervical lymphadenitis was made, resulting in hospital admission and treatment with intravenous piperacillin-tazobactam (4.5 g every 8 hours). Four days after the admission, his fever persisted and he developed new erythema at the right cervical region prompting a change of treatment to meropenem (1 g every 8 hours) and intravenous vancomycin (750 mg every 12 hours) for suspected cellulitis. The following day, the patient remained febrile and developed tachycardia, hypoxia and abdominal pain (figure 1). He was transferred to the intensive care unit (ICU) with a presumed diagnosis of bacterial sepsis from a cervical skin infection.

On day 6, the patient’s condition quickly deteriorated to a multiorgan failure with significant respiratory distress, hypotension, acute kidney injury, and elevated transaminases and troponin. He was intubated and treated with vasopressors and continuous renal replacement therapy (CRRT).

INVESTIGATIONS
On arrival to the ICU, the patient had two documented negative PCR COVID-19 tests (he eventually had four more while in the ICU, all of which were negative).

A full body CT scan on day 5 revealed stable right-sided cervical lymphadenopathy, with new extension of inflammation into the subcutaneous tissues along the lateral neck, new fluid in the right retropharyngeal space, prominent mediastinal lymph nodes, peribronchovascular confluent opacities and interlobular septal thickening with bilateral pleural effusions, as well as pancolitis with a small amount of ascites (figure 2).

Laboratory values from the day 6 decompensation revealed the following: haemoglobin of 94 g/L, platelets of $383 \times 10^9$, neutrophils of $34.9 \times 10^9$, lymphocytes of $1.08 \times 10^9$, monocytes of $1.93 \times 10^9$, C reactive protein of $3.84 \times 10^9$ mg/L and a ferritin level of $1.02 \times 10^9 \mu$g/L (table 1).

On the same day, the patient underwent open exploration of his right neck, which revealed no necrotic tissue nor pus. A cervical lymph node biopsy revealed a reactive lymph node without any evidence of tumour or granulomas. All microbial stains and cultures performed on the neck tissues were negative. An extensive infectious work-up (table 2) yielded negative results. An autoimmune work-up was negative as well.
A transthoracic echocardiogram (TTE) a day later revealed diffuse hypokinesis of the left ventricle with severe systolic dysfunction and an ejection fraction of 20%. A repeat ferritin was $8.40 \times 10^4 \mu g/L$, triglycerides were 2.28 mmol/L, lactate dehydrogenase was $6.32 \times 10^3 U/L$ and plasma interleukin 6 (IL-6) was $3.15 \times 10^2 ng/L$.

A suspicion for HLH led to a bone marrow aspirate which revealed haemophagocytosis (figure 3). No evidence of lymphoma or cytomegalovirus (CMV) intranuclear inclusions was seen; bacterial, mycobacterial and fungal cultures performed on the bone marrow aspirate showed no growth.

**DIFFERENTIAL DIAGNOSIS**

Given the combination of multiorgan failure, systemic inflammation and elevated cytokines, the patient seemed to be suffering from a cytokine storm. There exists, however, significant overlap in the diseases that constitute the cytokine storm spectrum. The differential diagnoses included bacterial sepsis, toxic shock syndrome, viral infection, autoinflammatory disorder (such as systemic lupus erythematosus, vasculitis), multicentric Castleman disease and other human herpes virus-8-related conditions, secondary HLH, and multisystem inflammatory syndrome associated with SARS-CoV-2.

At the time of decompensation, the patient met three of eight HLH 2004 criteria with a calculated HScore of 162, indicating a 40%–54% probability of a haemophagocytic syndrome.4 5 The addition of the bone marrow aspirate showing haemophagocytosis increased the patient’s HScore to 197 for an 80%–88% probability. Notably, the absence of acute Epstein-Barr virus (EBV), CMV and HIV infections and the unremarkable autoimmune panel also contributed to the diagnosis.

**TREATMENT**

Given the suspicion of HLH, the patient was treated with a pulse dose of 1000 mg of methylprednisolone pending the bone marrow aspirate result. The ferritin decreased to $7.63 \times 10^2 \mu g/L$ after 3 days of methylprednisolone.

On day 12 in hospital, the patient received a first dose of etoposide (175 mg) and started daily dexamethasone (18 mg) for 2 weeks.

On day 15, now haemodynamically stable, a repeat TTE showed an improvement of the left ventricular systolic function with an ejection fraction of 50%; therefore, only dexamethasone was continued and the patient was extubated. On day 16, however, the patient was again breathless, febrile and confused; ferritin reincreased to 7.77 $\times 10^2 \mu g/L$ after 3 days of methylprednisolone.

On day 28 in hospital, the patient received a third dose of etoposide, and dexamethasone had already been decreased (9 mg intravenously). His ferritin normalised to 2.91 $\times 10^2 \mu g/L$, as did the triglycerides to 1.56 mmol/L and the lactate dehydrogenase to 1.86 $\times 10^2 U/L$ (table 2).

**OUTCOME AND FOLLOW-UP**

Unfortunately, soon after, the patient developed bronchopleural fistula requiring lung-protective ventilation; this was thought to have been caused by barotrauma in the context of a COVID-19-related parenchymal lung injury. A repeat CT of the chest showed no evidence of fibrosis (figure 4). The fistula was managed by adopting a lung-protective ventilation strategy.

Next, as a consequence of adopting a lung-protective ventilation strategy, the patient developed hypercapnic respiratory failure. Due to significant hypercapnia and also due to difficulty oxygenating in the context of worsening adult respiratory distress syndrome (ARDS) from HLH combined with a lung-protective ventilation strategy, venovenous extracorporeal membrane oxygenation was started.

---

**Table 1** Laboratory results from days 0, 6, 15 and 28

| Laboratory test                          | Day 0 (in the emergency room) | Day 6     | Day 15   | Day 28   |
|------------------------------------------|-------------------------------|-----------|----------|----------|
| Haemoglobin (g/L)                        | 137                           | 94        | 75       | 73       |
| Platelets ($\times 10^{12}/L$)           | 174                           | 383       | 267      | 229      |
| White cell count ($\times 10^{9}/L$)     | 18.0                          | 38.0      | 28.4     | 4.20     |
| Absolute neutrophils ($\times 10^{9}/L$) | 15.8                          | 34.9      | 27.9     | 3.61     |
| Absolute lymphocytes ($\times 10^{9}/L$) | 0.82                          | 1.08      | 0.20     | 0.27     |
| Absolute monocytes ($\times 10^{9}/L$)   | 1.25                          | 1.93      | 0.14     | 0.16     |
| Creatinine (μmol/L)                      | 71                            | 193       | 313      | 361      |
| Alanine aminotransferase (U/L)           | 36                            | 2.07 $\times 10^3$ | 62      | 24       |
| C reactive protein (mg/L)                | 310                           | 364       | 124      | 173      |
| Ferritin (μg/L)                          | Not done                      | 1.02 $\times 10^3$ | 952     | 291      |
| Triglycerides (mmol/L)                   | Not done                      | 2.28      | 1.60     | 1.23     |
| Lactate dehydrogenase (U/L)              | 174                           | 6.32 $\times 10^3$ | Not done | 263      |
| Interleukin 6 (ng/L)                     | Not done                      | 315       | Not done | Not done |

---

**Figure 1** Chest X-ray from day 4 demonstrating bilateral small pleural effusions, diffuse bilateral reticular densities, and right upper lobe and lower consolidations.

**Figure 2** CT angiogram of the chest from day 5 demonstrating peribronchovascular confluent opacities and interlobular septal thickening, bilateral pleural effusions and mild anasarca.
Case report

Oxygenation (ECMO) was initiated on day 31 (figure 5). On day 41, the patient underwent percutaneous tracheotomy (figure 6). On day 64, ECMO support was stopped as both oxygenation and ventilation were adequately performed by a ventilator.

Table 2  Infectious and autoimmune work-up performed between days 6 and 8

| Blood cultures | Urine culture | BAL culture | Mycoplasma pneumoniae BAL | Legionella BAL | PJP BAL | hantavirus BAL | aspergillus antigen BAL | galactomannan BAL |
|---------------|--------------|-------------|---------------------------|----------------|---------|----------------|------------------------|------------------|
| (−) x2        | (−)          | (−)         | (−)                       | (−)            | (−)     | (−)            | (−)                    | (−)              |
| Antinuclear Ab (−) at a titre of 1:160 | Anti-DNA Ab not done | | | | | | | |

SARS-CoV-2 NAAT on BAL (−), Biofire V2.1 plus multiplex-22 respiratory infections performed on BAL (−), TB sputum culture (−)

HIV Ab/Ag screen (−) Anti-MPO <2 RU/mL, anti-PR3 <2 RU/mL

Hepatitis B sAg (−), hepatitis B sAb=0.0 IU/L, hepatitis B cAb (−), hepatitis C Ab (−)

Lupus anticoagulant dRVVT screen 63.5 s, dRVVT confirm 1.37 ratio, PTTLA 61.7 s

Rheumatoid factor quantitative <10 IU/mL

Anti-DNA Ab not done

HIV Ab/Ag screen (−) Anti-MPO <2 RU/mL, anti-PR3 <2 RU/mL

Hepatitis B sAg (−), hepatitis B sAb=0.0 IU/L, hepatitis B cAb (−), hepatitis C Ab (−)

Lupus anticoagulant dRVVT screen 63.5 s, dRVVT confirm 1.37 ratio, PTTLA 61.7 s

Rheumatoid factor quantitative <10 IU/mL

At the time of this report, the patient is hospitalised in a ventilatory weaning unit where he is neurologically and haemodynamically stable.

DISCUSSION

Since its discovery in 1939, at which point it was known as histiocytic medullary reticulosis, HLH has proven to be a perplexing condition. Conventionally, HLH is grouped into two distinct categories: primary and secondary. Primary occurs...
more often in children, in the setting of a genetic predisposition, which disrupts cytotoxic T cell and inflammasome functions. Secondary occurs more often in adults, in the absence of a genetic predisposition, but in the context of an immunological trigger (infection, malignancy, etc). Both forms are engendered by a dramatic activation of cytotoxic T cells and natural killer cells combined with macrophage activation. Such an uncontrolled immune activation syndrome can lead to a cytokine storm, which can be life-threatening.

The incidence of HLH in adults is low, ranging from 1 in 2000 patients admitted to tertiary care centres to 1 in 800,000 seen in a Japanese nationwide survey. The mean age in adults is reported to be around 50 years, and approximately two-thirds of cases occur in men; it remains unclear whether certain races and ethnic groups are predisposed to developing HLH. Current guidelines recommend using the HLH 2004 criteria for diagnosis in adults; however, this recommendation is based on expert opinion, as these criteria have only been validated in children. The HScore, developed by Fardet et al, represents another diagnostic tool. Finally, flow cytometry of CD38 and human leukocyte antigen DR type (HLA-DR) expression on CD8 T cells has recently been proposed as another diagnostic aid.

With regard to treatment, the abovementioned guidelines recommend regimens that include etoposide with the target of inducing an immune-mediated remission of the underlying stressor, cardiac function is generally restored within 1–4 weeks, which is what occurred in this case.

It remains unclear why very few patients develop HLH after SARS-CoV-2 infection. It is hypothesised that an aberrant virus–host interaction occurs in the context of elevated cytokines, including IL-6 levels. IL-6 is a major driver of B cell hyperfunction leading to polyclonal expansion. Excessive release of IL-6 has been linked to numerous autoimmune diseases. Of note, tocilizumab, an anti-IL-6 receptor monoclonal antibody, was not administered in this case of postacute COVID-19 syndrome since it was thought that tocilizumab would not have blocked the phagocytosis process at the origin of the HLH. Naous et al described a 69-year-old woman who presented with HLH documented by a bone marrow aspiration 3 weeks after her COVID-19 infection. In contrast to this case, the patient presented within 4 weeks of her initial infection and she required hospitalisation as well as intravenous steroids during her initial infection. Despite treatment with dexamethasone and etoposide, the patient did not survive.

The presented case of HLH following a pauci-symptomatic COVID-19 infection illustrates a delayed and severely modified immune response against SARS-CoV-2 and represents a COVID-19-associated haemophagocytic lymphohistiocytosis (HLH) can present as a postacute COVID-19 syndrome, even after a pauci-symptomatic initial infection.

The development of HLH after a SARS-CoV-2 infection is rare and represents an aberrant virus–host interaction.

HLH remains a diagnostic challenge since it can mimic severe infections, autoimmune diseases, lymphoproliferative disorders and multisystem inflammatory syndrome in adults.

A bone marrow aspirate and/or biopsy should be performed on speculation to help facilitate an early diagnosis.

The optimal duration of immunosuppressive therapy should be made on a case-by-case basis due to the elevated risk of bone marrow suppression and infection.

Learning points
new entity on the list of postacute COVID-19 manifestations. A high index of suspicion is necessary for the diagnosis of HLH in patients who have recovered from COVID-19. Bone marrow aspiration and/or biopsy should be carried out promptly to confirm the diagnosis and start appropriate treatment for HLH.

There is currently no guidelines or algorithm for optimal follow-up of patients who have recovered from COVID-19. Nevertheless, several institutions have already created post-COVID-19 recovery clinics. A follow-up visit (or telemedicine visit) weeks to months after the initial infection, regardless of the severity, might help both to ensure resolution of the prior symptoms and assess for emerging postacute COVID-19 manifestations.

Contributors DW and GS devised the project and main conceptual ideas. DW reviewed the patient’s chart and wrote the manuscript under the supervision of J-PR and GS. J-PR provided feedback and helped shape the analysis and the manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

ORCID ID
Jean-Pierre Routy http://orcid.org/0000-0001-9897-7589

REFERENCES
1 World Health Organization. WHO Coronavirus (COVID-19) Dashboard [Internet]. 2021. Available: https://covid19.who.int/

Copyright 2021 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit https://www.bmj.com/company/products-services/rights-and-licensing/permissions/
BMJ Case Report Fellows may re-use this article for personal use and teaching without any further permission.

Become a Fellow of BMJ Case Reports today and you can:
► Submit as many cases as you like
► Enjoy fast sympathetic peer review and rapid publication of accepted articles
► Access all the published articles
► Re-use any of the published material for personal use and teaching without further permission

Customer Service
If you have any further queries about your subscription, please contact our customer services team on +44 (0) 207111 1105 or via email at support@bmj.com.
Visit casereports.bmj.com for more articles like this and to become a Fellow

Wiseman D, et al. BMJ Case Rep 2021;14:e245031. doi:10.1136/bcr-2021-245031

2 Yang K, Xing M-Y, Jiang L-Y, et al. Infection-associated hemophagocytic syndrome in critically ill patients with COVID-19. Curr Med Sci 2021;41:39–45.
3 Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med 2021;27:601–15.
4 Henter JI, Horne A, Aricó M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007;48:124–31.
5 Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol 2014;66:2613–20.
6 Al-Samkari H, Berliner N. Hemophagocytic lymphohistiocytosis. Annu Rev Pathol 2018;13:27–49.
7 Knight V, Heimall JR, Chong H, et al. A toolkit and framework for optimal laboratory evaluation of individuals with suspected primary immunodeficiency. J Allergy Clin Immunol Pract 2021. doi:10.1016/j.jaip.2021.05.004. [Epub ahead of print: 24 May 2021].
8 Parikh SA, Kapoor P, Letendre L, et al. Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. Mayo Clin Proc 2014;89:484–92.
9 Ishii E, Ogha S, Imashuku S, et al. Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol 2007;86:58–65. doi:10.1532/ IJH97.07012
10 Chaturvedi V, Marsh RA, Zoref-Lorenza A, et al. T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis. Blood 2021;137:2337–46.
11 La Rosée P, Horne A, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood 2019;133:2465–77.
12 Ramos-Casals M, Brito-Zerón P, López-Guillermo A, et al. Adult haemophagocytic syndrome. Lancet 2014;383:1503–16.
13 Retamozo S, Brito-Zerón P, Sís-Adimirall A, et al. Haemophagocytic syndrome and COVID-19. Clin Rheumatol 2021;40:1233–44.
14 Morris SB, Schwartz NG, Patel P, et al. Case Series of Multisystem Inflammatory Syndrome in Adults Associated with SARS-CoV-2 Infection – United Kingdom and United States, March-August 2020. MMWR Morb Mortal Wkly Rep 2020;69:1450–6.
15 Akashi YJ, Goldstein DS, Barbaro G, et al. Takotsubo cardiomyopathy: a new form of acute, reversible heart failure. Circulation 2008;118:2754–62.
16 Tanaka T, Narazaki M, Kishimoto T. Interleukin (IL-6) immunotherapy. Circulation 2014;130:1450–6.
17 Nanao E, Nasani B-M, Yaghi C, et al. Hemophagocytic lymphohistiocytosis, a new cause of death during ‘post-acute COVID-19 syndrome?’ A case report. J Hematop 2021:1–5.